Recombinant activated protein C induces dose-dependent changes in inflammatory mediators, tissue damage, and apoptosis in in vivo rat model of sepsis

Surgical Infections

Volumn 8, Issue 3, 2007, Pages 377-386

  Shires, G Tom ^a   Fisher, Orna ^a   Murphy, Patrick ^a   Williams, Shelley ^a   Barber, Annabel ^a   Johnson, Gayle ^a   Davis, Brett ^a   Pahulu, Stacey ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; INTERLEUKIN 6; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; ESCHERICHIA COLI; IN VIVO STUDY; INFLAMMATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SEPSIS; SPRAGUE DAWLEY RAT; TISSUE INJURY;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI INFECTIONS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; PROTEIN C; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SEPSIS; SERINE ENDOPEPTIDASES;

EID: 34547545123     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.082     Document Type: Article

References (28)

1. Anderson N, Smith BL. CDC National Vital Statistics Reports 2005;53(17).
2. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517-524.
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
4. Mazolewski PJ, Barber A, Williams S, et al. Attenuating tumor necrosis factor alpha does not ameliorate other cytokine and peroxidase products during sepsis. Am J Surg 1999;178:556-559.
5. Eli Lilly. Xigris package insert. Indianapolis, IN, Eli Lilly & Co., 2002.
6. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
7. Abraham E. Effects of recombinant human activated protein C in human models of endotoxin administration. Proc Am Thorac Soc 2005;2:243-247.
8. Vincent JL, Bernard GR, Beale R. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Crit Care Med 2005;33:2266-2277.
9. Bernard GR, Margolis BD, Shanies HM, et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): A single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125:2206-2216.
10. Erdelmeier I, Gerard-Monnier D, Yadan JC, Chaudiese J. Reactions of N-methyl-2-phenlindole with malondialdehyde and 4-hydroxyalkenals: Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem Res Toxicol 1997;11:1184-1194.
11. Staley K, Blaschke AJ, Chun J. Apoptotic DNA fragmentation is detected by a semi-quantitative ligation-mediated PCR of blunt DNA ends. Cell Death Differ 1997;4:66-75.
12. Looney MR, Matthay MA. The role of protein C in sepsis. Curr Infect Dis Rep 2001;5:413-418.
13. McGilvray ID, Rotstein OD. Role of the coagulation system in the local and systemic inflammatory response. World J Surg 1998;2:179-186.
14. Iba T, Kidokoro A, Fukunaga M, et al. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33:368-372.
15. Papathanassoglu ED, Moynihan JA, Ackerman MH. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? Crit Care Med 2000;28:537-549.
16. Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL. Apoptosis in sepsis: A new target for therapeutic exploration. FASEB J 2001;15:879-892.
17. Hiramatsu M, Hotchkiss RS, Karl IE, Buchman TG. Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF-independent pathway. Shock 1997;7:247-253.
18. Maeda K, Abello PA, Abraham MR, Wetzel RC, et al. Endotoxin induces organ-specific endothelial cell injury. Shock 1995;3:46-50.
19. Kolgazi M, Sener G, Cetinel S, et al. Resveratrol reduces renal and lung injury caused by sepsis in rats. J Surg Res 2006;134:315-321.
20. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;275:11199-11203.
21. O'Brien LA, Gupta A, Grinnell BW. Activated protein C and sepsis. Front Biosci 2006;1:676-698.
22. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373:65-70.
23. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990;9:515-540.
24. Shorr AF, Bernard GR, Dhainaut JF, et al. Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome. Crit Care 2006;10:R92-R100.
25. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L514-L521.
26. Bernard GR, Macias WL, Joyce DE, et al. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003;7:155-163.
27. Alsfasser G, Warshaw AL, Thayer SP, et al. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg 2006;141:670-677.
28. Parrillo JE. Severe sepsis and therapy with activated protein C. N Engl J Med 2005;353:1398-1400.